Metabolic factors and high-sensitivity C-reactive protein: The HUNT study

European Journal of Preventive Cardiology

Volumn 19, Issue 5, 2012, Pages 1101-1110

  Laugsand, Lars E ^a   Åsvold, Bjørn Olav ^a,b   Vatten, Lars J ^a   Romundstad, Pål R ^a   Wiseth, Rune ^a,b   Hveem, Kristian ^a   Janszky, Imre ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Age; hsCRP; metabolic syndrome; sex

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NORWAY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; AGE DISTRIBUTION; BLOOD; COMPARATIVE STUDY; FOLLOW UP; HEALTH SURVEY; METABOLISM; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO;

AGE DISTRIBUTION; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NORWAY; POPULATION SURVEILLANCE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION;

EID: 84873272367     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711417758     Document Type: Article

References (55)

1. Desprès JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol. 1994 ; 5 (4). 274-289
2. Desprès JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996 ; 334 (15). 952-958
3. Isomaa B, Almgren P, Tuomi T, Forsèn B, Lahti K, Nissèn M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 ; 24 (4). 683-689
4. Chen K, Lindsey JB, Khera A, Lemos JAD, Ayers CR, Goyal A, et al. Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. Diab Vasc Dis Res. 2008 ; 5 (2). 96-101
5. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002 ; 25 (11). 2016-2021
6. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003 ; 168 (2). 351-358
7. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 ; 102 (1). 42-47
8. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PWF. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004 ; 110 (4). 380-385
9. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003 ; 107 (3). 391-397
10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 ; 286 (3). 327-334
11. Duncan BB, Schmidt MI, Pankow JS, Ballantyne C, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes. Diabetes. 2003 ; 52 (7). 1799-1805
12. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004 ; 53: 693-700
13. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000 ; 23 (12). 1835-1839
14. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010 ; 74 (2). 213-220
15. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010 ; 31 (7). 777-783
16. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000 ; 321 (7255). 199-204
17. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eirksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004 ; 350 (14). 1387-1397
18. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly D, Haffner SM, et al. Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003 ; 108 (4). 414-419
19. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004 ; 351 (25). 2599-2610
20. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107 (3). 499-511
21. Holman RL. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the 20th century. Am J Pathol. 1958 ; 34 (2). 209-235
22. Tejada C. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab Invest. 1968 ; 18 (5). 509-526
23. McNamara JJ. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971 ; 216 (7). 1185-1188
24. Virmani R, Robinowitz M, Geer JC, Breslin PP, Beyer JC, McAllister HA. Coronary artery atherosclerosis revisited in Korean war combat casualties. Arch Pathol Lab Med. 1987 ; 111 (10). 972-976
25. Patel DA. Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metabolism. 2006 ; 55 (6). 699-705
26. de Ferranti SD, Gauvreau K, Ludwig DS, Newburger JW, Rifai N. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem. 2006 ; 52 (7). 1325-1330
27. Holmen J, Midthjell K, Kruger Ø, Langhammer A, Holmen T, Bratberg G, et al. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): objectives, contents, methods and participation. Norsk Epidemiologi. 2003 ; 13 (1). 19-32
28. Mørkedal B, Laugsand LE, Romundstad PR, Vatten LJ. Mortality from ischaemic heart disease: sex-specific effects of transferrin saturation, serum iron, and total iron binding capacity. The HUNT study. Eur J Cardiovasc Prevent Rehabil. 2011 ;:
29. Imhof A, Frohlich M, Loewel H, Halbecque N, Woodward M, Amouyel P, et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem. 2003 ; 49 (4). 669-672
30. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003 ; 49 (8). 1258-1271
31. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donata KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
32. Craig S, Amin R, Russell D, Paradise N. Blood cholesterol screening. J Gen Intern Med. 2000 ; 15 (6). 395-399
33. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol. 1999 ; 19 (4). 972-978
34. Onat A, Ceyhan K, Basar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis. 2002 ; 165 (2). 285-292
35. Guerrero-Romero F, Rodríguez-Morán M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003 ; 29 (1). 65-71
36. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care. 2005 ; 28 (3). 690-693
37. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 2004 ; 109 (23). 2818-2825
38. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005 ; 165 (21). 2479-2484
39. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998 ; 279 (20). 1615-1622
40. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg cohort study, 1984-1998. Clin Chem. 2008 ; 54 (2). 335-342
41. Devaraj S, Valleggi S, Siegel D, Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atherosclerol Rep. 2010 ; 12 (2). 110-118
42. Suzuki T, Hirata K, Elkind MSV, Jin Z, Rundek T, Miyaka Y, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J. 2008 ; 156 (9501). 405-410
43. Bisoendial RJ, Birjmohun RS, Akdim F, van't Veer C, Spek CA, Hartman D, et al. C-reactive protein elicits white blood cell activation in humans. Am J Med. 2009 ; 122 (6). 582.e581 - e582, e589
44. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day INM, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet. 2005 ; 366 (9501). 1954-1959
45. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997 ; 82 (12). 4196-4200
46. Lowe GDO. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005 ; 3 (8). 1618-1627
47. Berenson GS, Wattigney WA, Tracy RE, Newman WP, Srinivasan SR, Webber LS, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (the Bogalusa Heart Study). Am J Cardiol. 1992 ; 70 (9). 851-858
48. Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine study. J Am Coll Cardiol. 1996 ; 27 (2). 277-284
49. McMahan CA, McGill HC, Gidding SS, Malcolm GT, Newman WP, Tracy RE, et al. PDAY risk score predicts advanced coronary artery atherosclerosis in middle-aged persons as well as youth. Atherosclerosis. 2007 ; 190 (2). 370-377
50. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem. 2003 ; 49 (4). 666-669
51. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999 ; 100 (7). 713-716
52. Khera A, McGuire DK, Murphy SA, Stankek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005 ; 46 (3). 464-469
53. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006 ; 152 (3). 593-598
54. Fröhlich M, Döring A, Imhof A, Hutchinson WL, Pepys MB, Koenig W. Oral contraceptive use is associated with a systemic acute phase response. Fibrinolysis and Proteolysis. 1999 ; 13 (6). 239-244
55. Fröhlich M, Mühlberger N, Hanke H, Imhof A, Döring A, Pepys MB, et al. Markers of inflammation in women on different hormone replacement therapies. Ann Med. 2003 ; 35 (5). 353-361